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In the current issue of the Canadian Respiratory Journal, Tulek et al (1) (pages 91-96) examined the concept that high-resolution x-ray 
computed tomography (CT) measurements of airway and parenchyma 
abnormalities in chronic obstructive pulmonary disease (COPD) could 
be used to classify patients into clinically relevant subgroups with 
resulting differences in lung function, markers of inflammation and 
exacerbation rates. In a relatively small group of COPD patients (n=80: 
small compared with the recently reported Genetic epidemiology of 
COPD [COPDGene (2)] and Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate End-points [ECLIPSE (3) studies]), thor-
acic CT was acquired and visually evaluated by two experts using a 
modified Bhalla scoring system (4) – an approach more commonly 
used for cystic fibrosis imaging evaluations. On this basis, patients were 
classified into one of four groups: no imaging findings related to 
COPD; emphysema only; bronchiectasis/peribronchial thickening 
only; and emphysema in combination with bronchiectasis/peribron-
chial thickening. While 54 subjects demonstrated CT imaging evi-
dence of emphysema or airway abnormalities, or both, 26 patients 
showed no CT abnormalities. Importantly, spirometry and other find-
ings were worse for the subgroups with a CT-derived COPD phenotype 
than the subgroup with no findings. In addition, as might be intui-
tively expected (but not previously reported), the subgroup with only 
emphysema showed less severe pulmonary function results, inflamma-
tion and fewer exacerbations, whereas the group with both emphy-
sema and airway abnormalities exhibited significantly lower lung 
function values, higher levels of C-reactive protein and erythrocyte 
sedimentation rates, and more exacerbations. 
COPD is recognized as a regionally heterogeneous disease with 
underlying contributions from airway abnormalities (5) or, perhaps, air-
way obliteration (6) and emphysematous destruction. Recent patho-
logical analyses using micro-CT have suggested that there is a loss of 
terminal bronchioles that temporally precedes emphysematous changes 
in COPD (6). It is well recognized that COPD is heterogeneous across 
individuals and regionally in the lung, and the exact temporal relation-
ship of morphological changes in the airways and parenchyma has not 
yet been definitively established. What is clear, however, is that spirom-
etry measurements provide less-than-ideal estimates or predictors of 
COPD onset and progression, response to treatment and exacerbation 
frequency (7). In light of this, CT has been proposed as a noninvasive 
method to provide regional measurements of the underlying morpho-
logical changes that directly result in COPD symptoms and exacerba-
tions. Although the concept of COPD patient classification beyond 
forced expiratory volume in 1 s is decades old, it has recently been re-
evaluated using CT in light of the large and exhaustive COPDGene (2) 
and ECLIPSE studies (3), and proposed as a way to discriminate patients 
with unique morphological, clinical and physiological characteristics. 
CT phenotyping provides a method to group or categorize patients based 
on imaging findings, and these can be statistically evaluated with respect 
to a myriad of laboratory findings, symptoms and other pathologies 
related to COPD; in addition, the underlying structure-function rela-
tionships that are determined can potentially be used to direct or at least 
guide treatment.  
High-resolution CT images of airway morphology, parenchyma 
density and gross anatomy have been analyzed to determine phenotypes 
of COPD and classify patients into disease severity subgroups. For 
example, using COPDGene data, Galban et al (8) developed an ele-
gant approach to derive parametric response maps and identify CT 
phenotypes. Their results support the concept that airways disease 
precedes emphysema in early stage COPD, whereas when COPD pro-
gresses, both emphysema and airways disease are present. Using the 
same cohort of COPDGene patients, the relationship between exacer-
bation frequency and emphysema-predominant or airways disease-
predominant CT phenotypes was evaluated (9). Here, exacerbation 
frequency was shown to be related to both emphysema and airway 
disease-dominant phenotypes and, in the case of mixed emphysema-
airways disease phenotypes, exacerbation frequency was decreased but 
quality of life was much worse.  
How can this information be used in the future? Do the risks and 
resources inherent in acquiring CT data outweigh the important infor-
mation content and the potential to alter therapy decisions in COPD? 
In a resource-limited setting, outside of a major clinical trial, a careful 
clinical study involving a small group of smokers with COPD, such as 
presented by Tulek et al (1), provides intriguing evidence that CT 
phenotypes may help explain exacerbation risk, predict underlying 
inflammation and, perhaps, stratify patients. Indeed, the study by 
Tulek et al (1) demonstrates the importance of CT phenotyping, even 
in a small group of patients, and urges us to continue developing more 
robust, safer and less resource-intensive imaging phenotypes of COPD. 
Future steps necessarily include automated image analysis tools to 
reduce the time and variability inherent in manual analyses and 
finally, a randomized controlled trial to evaluate COPD outcomes 
based on therapy decisions made with and without imaging phenotype 
information.  
Phenotyping promises potentially better therapy and outcomes for 
COPD patients, and this study makes it clear that now is the time to 
start making good on this promise.
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